Rohit Parehk
Direktor/Vorstandsmitglied bei Cora Therapeutics, Inc.
Profil
Rohit Parehk currently works as a Director at Cora Therapeutics, Inc.
Aktive Positionen von Rohit Parehk
Unternehmen | Position | Beginn |
---|---|---|
Cora Therapeutics, Inc.
Cora Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Cora Therapeutics, Inc. is a data-driven health solutions company based in Toronto, CA. The product is clinically proven and patented to minimize the irreversible damage to DNA caused by radiation from medical imaging such as CT and X-ray, and cosmic radiation on planes at high altitudes. The Canadian company, under the leadership of Dr. Kieran Murphy, a renowned interventional neuroradiologist, is committed to minimizing the collateral damage caused by radiation exposure. The team is complemented by the esteemed scientific advisor, Dr. Mark Tarnopolsky, who is a frontrunner in evaluating and developing nutraceutical treatments for disorders associated with oxidative stress. The company's first product, Halo antioxidant, is launching in 2022. The company's formulations are developed using the wealth of knowledge possessed by their team and validated through clinical research. The company was founded by Kieran Murphy, and the CEO is David Simpson. | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Cora Therapeutics, Inc.
Cora Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Cora Therapeutics, Inc. is a data-driven health solutions company based in Toronto, CA. The product is clinically proven and patented to minimize the irreversible damage to DNA caused by radiation from medical imaging such as CT and X-ray, and cosmic radiation on planes at high altitudes. The Canadian company, under the leadership of Dr. Kieran Murphy, a renowned interventional neuroradiologist, is committed to minimizing the collateral damage caused by radiation exposure. The team is complemented by the esteemed scientific advisor, Dr. Mark Tarnopolsky, who is a frontrunner in evaluating and developing nutraceutical treatments for disorders associated with oxidative stress. The company's first product, Halo antioxidant, is launching in 2022. The company's formulations are developed using the wealth of knowledge possessed by their team and validated through clinical research. The company was founded by Kieran Murphy, and the CEO is David Simpson. | Commercial Services |